CERUS CORP

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.

Cerus Corporation은 생체의료 제품 기업입니다. 이 회사는 혈액 안전성을 향상시키기 위한 INTERCEPT Blood System의 개발 및 상용화에 주력하고 있습니다. 수혈용으로 기증된 혈액 성분 내 혈액 매개 병원체를 줄이도록 설계된, 생물학적 복제 제어 독점 기술인 INTERCEPT Blood System을 제공합니다. 또한, 수혈용으로 기증된 혈소판 및 혈장의 혈액 매개 병원체 비활성화를 위한 INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation; 수혈용 적혈구의 혈액 매개 병원체 비활성화를 위한 INTERCEPT Blood System for red blood cells; 그리고 자사의 혈장 시스템을 사용하여 피브